$1.30—Stale · unknown old
NASDAQ • Last print unknown ago
$1.30—Stale · unknown old
Codex DNA, Inc. specializes in synthetic biology and DNA synthesis technologies, offering solutions for gene synthesis and genomic data management. The company's proprietary platform enables rapid and cost-effective DNA construction, positioning it as a key player in the biotechnology sector, particularly in the U.S. and European markets.
Codex DNA generates revenue primarily through its advanced DNA synthesis services, which are critical for research and development in pharmaceuticals and biotechnology. The company leverages its proprietary technology to offer competitive pricing and faster turnaround times compared to traditional methods, providing a unique advantage in the rapidly growing synthetic biology market.
Adoption rates of synthetic biology technologies in pharmaceuticals
Partnership announcements with biotech firms for DNA synthesis
Regulatory approvals for new applications of its technology
Changes in R&D spending trends in the biotech sector
Technological disruption from emerging synthetic biology competitors
Regulatory changes affecting biotechnology research and applications
Increased competition from established biotech firms with more resources
Potential market entry of new players with innovative technologies
High debt levels relative to equity may constrain financial flexibility
Negative cash flow could limit operational sustainability
moderate - As a healthcare technology company, Codex DNA's performance is somewhat tied to overall economic conditions, particularly in R&D spending, which can fluctuate with GDP growth.
Higher interest rates could increase financing costs for Codex DNA, impacting its ability to invest in R&D and expansion. Additionally, elevated rates may dampen venture capital funding in the biotech sector, affecting demand for its services.
minimal - The company does not heavily rely on credit for its operations, although higher debt levels could impact its financial flexibility.
growth - Investors seeking exposure to innovative biotech solutions and high revenue growth potential.
high - The stock has exhibited significant volatility, particularly given its recent performance and market sentiment.